Aptose Biosciences Inc. (NASDAQ:APTO) Given Average Recommendation of “Buy” by Analysts

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been given an average rating of “Buy” by the five brokerages that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have covered the stock in the last year is $19.80.

Several equities analysts recently commented on the stock. Piper Sandler restated an “overweight” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Aptose Biosciences in a research note on Wednesday, March 27th. Finally, StockNews.com upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th.

Aptose Biosciences Stock Performance

APTO stock opened at $1.27 on Wednesday. The company’s 50-day simple moving average is $1.67 and its 200 day simple moving average is $2.18. Aptose Biosciences has a 52 week low of $1.20 and a 52 week high of $8.70. The company has a market capitalization of $19.96 million, a PE ratio of -0.16 and a beta of 1.29.

Institutional Investors Weigh In On Aptose Biosciences

A number of large investors have recently bought and sold shares of APTO. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Aptose Biosciences during the 4th quarter worth approximately $32,000. Sequoia Financial Advisors LLC acquired a new stake in Aptose Biosciences in the 1st quarter valued at $27,000. Annandale Capital LLC boosted its holdings in Aptose Biosciences by 40.0% during the 3rd quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 21,334 shares during the last quarter. Cetera Advisors LLC boosted its holdings in Aptose Biosciences by 40.1% during the 4th quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 24,847 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Aptose Biosciences by 3.6% during the 1st quarter. Renaissance Technologies LLC now owns 976,577 shares of the biotechnology company’s stock worth $1,328,000 after acquiring an additional 33,952 shares during the last quarter. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.